"Russia has the world's seventh largest pharmaceutical market, over US$14 billion in 2014" (Government of Russia, @GovernmentRF, 29 October 2015)
"Despite all the challenges that we have been faced with in our market region CIS/Eastern Europe during the last few months, we continue to build on our business activities in Russia and are convinced of its long-term potential" (Hartmut Retzlaff, Chairman of the Executive Board, Stada Arzneimittel AG, 15 September 2015)
"80 per cent of those surveyed continue, on the whole, to pursue their plans for business development in the Russian market in spite of the unstable political and economic situation and the current sanctions against Russia" (EY, The Russian Pharmaceutical Industry Amid Economic Sanctions, June 2015)
"Last year, a roadmap was approved to promote biotechnology and genetic engineering until 2020. Our objective is quite ambitious – to increase the contribution of the biotech industry to around 1% of the country’s GDP by 2020 and 3% by 2030" - Dmitrii Medvedev, Russian Prime Minister, 17 June 2014
"In 2013, the Russian pharmaceutical market grew by almost 8 per cent and exceeded 820 billion roubles. This market is estimated to exceed one trillion roubles in the coming years" - Dmitrii Medvedev, Russian Prime Minister, 16 May 2014
"The total size of the Russian market for medicines and nutritional supplements in 2012 was 818 billion RUB in the consumer price equivalent (3 per cent of the global market, 8th place globally), in a market where almost 80 per cent of products are imported" - Deloitte, 2013
"Russia is committed to building its biotech industry by forming partnerships with the leading world players. We aim to boost domestic production of generics and innovative pharmaceuticals through a major programme of co-licensing and investment in first-class infrastructure and education programmes. Cooperation with international leaders in drug discovery and development is essential if we are to transform the Russian biotech industry" - Denis Manturov, Russian Minister of Industry & Trade, 18 June 2012
Biopharm Analytica offers a range of bespoke consulting and research services with regard to the life sciences sector in Russia and the Newly Independent States. The UK-based company has undertaken market surveys for leading biotechnology multinationals and completed studies of niche technologies and markets. To discuss your detailed requirements with one of our analysts please call +44 (0)121 2702854.
Biopharm Analytica also provides access to an independent English language online business news and information service focusing on developments in biotechnology and the pharmaceutical industry in Russia and the Newly Independent States (NIS). One of its key focuses is on the identification of potential opportunities for international companies with a strong emphasis on high-value projects. Coverage is also provided of ongoing life sciences R&D and manufacturing within the region. Annual subscription to Biopharm Analytica by registered users, will allow immediate and privileged access to the information service covering major news stories impacting upon the biotechnology and pharmaceutical sectors in Russia and the NIS. A major searchable on-line database of news reports covering the period 2004-2015, providing an invaluable source of business intelligence with regard to the Russian biopharmaceutical sector, is available only to subscribers. Biopharm Analytica's news service is an indispensable adjunct to companies and analysts seeking real-time news and information focused on the Russian and NIS life sciences sector. To discuss your subscription requirements with one of our sales staff please call +44 (0)121 2702854 or email firstname.lastname@example.org.
© Biopharm Analytica Limited 2015. All Rights Reserved. This site is owned and operated by Biopharm Analytica Limited. Registered Office: Suite B, 29 Harley Street, London, W1G 9QR. Registered in England and Wales. Reg. No. 5360763. VAT Reg. No. 930 3219 57.